ReviewAmerican journal of respiratory and critical care medicine2015
Novel approaches are needed to develop tomorrow's antibacterial therapies.
Review in American journal of respiratory and critical care medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed.
- Selective Human-Milk-Inspired Antimicrobial Peptides for the Treatment of Bacterial Vaginosis.Pharmaceutics · 2026Article
- A comprehensive review of emerging therapeutic strategies against methicillin-resistantFrontiers in microbiology · 2026Review
- In-Silico discovery of novel cephalosporin antibiotic conformers via ligand-based pharmacophore modelling and de novo molecular design.Journal, genetic engineering & biotechnology · 2025Article
- Harnessing the Potential of Antibacterial and Antibiofilm Phytochemicals in the Combat Against Superbugs: A One Health Perspective.Antibiotics (Basel, Switzerland) · 2025Review
- Unravelling the Antibiotic Resistance: Molecular Insights and Combating Therapies.Applied biochemistry and biotechnology · 2025Review
- Standardization of the Agar Plate Method for Bacteriophage Production.Antibiotics (Basel, Switzerland) · 2024Article
- A Screen of Traditional Chinese Medicinal Plant Extracts Reveals 17 Species with Antimicrobial Properties.Antibiotics (Basel, Switzerland) · 2024Article
- Potential Synergy of Fluoxetine and Antibacterial Agents Against Skin and Soft Tissue Pathogens and Drug-Resistant Organisms.Antibiotics (Basel, Switzerland) · 2024Article
- Antimicrobial Activity of Some Steroidal Hydrazones.Molecules (Basel, Switzerland) · 2023Article
- Recent Approaches for Downplaying Antibiotic Resistance: Molecular Mechanisms.BioMed research international · 2023Review
- Synthesis and Structure-Activity Relationship of Thioacetamide-Triazoles againstMolecules (Basel, Switzerland) · 2022Article
- Grand challenge of antibiotics resistance: A global, multidisciplinary effort is needed.Frontiers in antibiotics · 2022Article
- Pneumonia.Nature reviews. Disease primers · 2021Review
- A How-To Guide for Mode of Action Analysis of Antimicrobial Peptides.Frontiers in cellular and infection microbiology · 2020Review
- Microbial Resistance Movements: An Overview of Global Public Health Threats Posed by Antimicrobial Resistance, and How Best to Counter.Frontiers in public health · 2020Review
- Clinical Utility of Lefamulin: If Not Now, When?Current infectious disease reports · 2020Review
- Biomarkers and clinical scores to identify patient populations at risk of delayed antibiotic administration or intensive care admission.Critical care (London, England) · 2019Article
- Antibiotic Killing of Diversely Generated Populations of Nonreplicating Bacteria.Antimicrobial agents and chemotherapy · 2019Article
- Peptidoglycan Recognition Protein 2 Regulates Neutrophil Recruitment Into the Lungs AfterFrontiers in microbiology · 2019Article
- Design and characterization of a new hybrid peptide from LL-37 and BMAP-27.Infection and drug resistance · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Society faces a crisis of rising antibiotic resistance even as the pipeline of new antibiotics has been drying up. Antibiotics are a public trust; every individual's use of antibiotics affects their efficacy for everyone else. As such, responses to the antibiotic crisis must take a societal perspective. The market failure of antibiotics is due to a combination of scientific challenges to discovering and developing new antibiotics, unfavorable economics, and a hostile regulatory environment. Scientific solutions include changing the way we screen for new antibiotics. More transformationally, developing new treatments that seek to disarm pathogens without killing them, or that modulate the host inflammatory response to infection, will reduce selective pressure and hence minimize resistance emergence. Economic transformation will require new business models to support antibiotic development. Finally, regulatory reform is needed so that clinical development programs are feasible, rigorous, and clinically relevant. Pulmonary and critical care specialists can have tremendous impact on the continued availability of effective antibiotics. Encouraging use of molecular diagnostic tests to allow pathogen-targeted, narrow-spectrum antibiotic therapy, using short rather than unnecessarily long course therapy, reducing inappropriate antibiotic use for probable viral infections, and reducing infection rates will help preserve the antibiotics we have for future generations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.